JP2023502777A5 - - Google Patents

Info

Publication number
JP2023502777A5
JP2023502777A5 JP2022530229A JP2022530229A JP2023502777A5 JP 2023502777 A5 JP2023502777 A5 JP 2023502777A5 JP 2022530229 A JP2022530229 A JP 2022530229A JP 2022530229 A JP2022530229 A JP 2022530229A JP 2023502777 A5 JP2023502777 A5 JP 2023502777A5
Authority
JP
Japan
Prior art keywords
formulation
liquid
viscosity
liquid formulation
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/062051 external-priority patent/WO2021108427A1/en
Publication of JP2023502777A publication Critical patent/JP2023502777A/ja
Publication of JP2023502777A5 publication Critical patent/JP2023502777A5/ja
Pending legal-status Critical Current

Links

JP2022530229A 2019-11-26 2020-11-24 バイオポリマー製剤のための賦形剤化合物 Pending JP2023502777A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940683P 2019-11-26 2019-11-26
US62/940,683 2019-11-26
PCT/US2020/062051 WO2021108427A1 (en) 2019-11-26 2020-11-24 Excipient compounds for biopolymer formulations

Publications (2)

Publication Number Publication Date
JP2023502777A JP2023502777A (ja) 2023-01-25
JP2023502777A5 true JP2023502777A5 (https=) 2023-12-04

Family

ID=76129670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022530229A Pending JP2023502777A (ja) 2019-11-26 2020-11-24 バイオポリマー製剤のための賦形剤化合物

Country Status (5)

Country Link
EP (1) EP4065166A4 (https=)
JP (1) JP2023502777A (https=)
KR (1) KR20220122993A (https=)
CA (1) CA3159377A1 (https=)
WO (1) WO2021108427A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
ES2936387T3 (es) * 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
US10478498B2 (en) * 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
NZ732511A (en) * 2014-12-15 2018-11-30 Univ Michigan Regents Small molecule inhibitors of egfr and pi3k
CA3002373A1 (en) * 2015-10-23 2017-04-27 Reform Biologics, Llc Excipient compounds for biopolymer formulations

Similar Documents

Publication Publication Date Title
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP6934919B2 (ja) 高度に濃縮された薬学的製剤
TWI860988B (zh) 低ph藥物製劑
CA2648644C (en) Muscle regeneration promoter
CA2626688C (en) Agents for treating cardiopathy
EP3580230B1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
US20090220499A1 (en) Agents for Suppressing Damage to Transplanted Islets After Islet Transplantation
KR20140108562A (ko) 변이체 액티빈 수용체 폴리펩티드 단독 또는 화학 치료법과의 결합, 및 그들의 용도
JP2017515815A (ja) レナリドミド及びポリペプチド構築物の組合せ、及びその使用
TW201625221A (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP2022507606A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
CN114762678B (zh) 抗tigit抗体药物组合物及其用途
WO2021128027A1 (zh) TACI-Fc融合蛋白及其用途
JP2023502777A5 (https=)
EA025365B1 (ru) Применение антитела к cd37 для лечения пациента из группы высокого риска, страдающего хроническим лимфолейкозом (cll), способ истощения экспрессирующих cd37 в-клеток в популяции клеток с дефицитом тр53
CN117940169A (zh) 抗体药物偶联物的用途及联合用药物及其用途
US20130017197A1 (en) Stabilized antibody preparations and uses thereof
JP2021522241A5 (https=)
US20220298249A1 (en) Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
CN116440263A (zh) 抗ctla-4抗体药物组合物及其用途
JP2024501770A (ja) シアリダーゼ－ｐｄ－１－抗体融合タンパク質及びその使用方法
JP2023550310A (ja) 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト
WO2025113598A1 (zh) 稳定的混合抗体的药物组合物
US20250262199A1 (en) Treatment of autoimmune skin disease
CN115531298A (zh) 稳定的抗TNFα单克隆抗体的液体制剂